Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Jabak Discussed with the Syndicate of Hospitals Owners the Health Sector Issues and Received an Invitation to Attend the Arab Hospitals Forum in Cairo

 
The Minister of Public Health Jamil Jabak received a delegation from the private hospitals owners syndicate headed by Sleiman Haroun, in the presence of MP Fadi Alama. During a meeting, hospitals matters and the ways to find solutions for the problems of the citizens and the hospitals’ owners were discussed.
 
“We consider them as an integral part of the hospitalization sector in Lebanon and a key partner in the health care and medical sector in Lebanon,” Jabak told the delegation.
 
Dr. Jabak said that the meeting tackled the problems of the syndicate and mentioned that the ministry would work to find solutions to these problems in no time.
 
Haroun

Haroun stated that the visit aimed at congratulating Dr. Jabak for taking office at the Ministry. “The meeting provided an opportunity to consider the matters that need to be dealt with on the long term,” Jabak added.
 
“The delegation noticed Minister Jabak’s concern for the hospitals as much as for the patient and the need to provide him with the necessary services. It was agreed to activate the current scientific mechanism related to the admission of the patient to the emergency room at the hospitals in order to prevent any issues that might arise while admission,” Haroun said.
 
“The syndicate’s delegation asked the Minister of Public health to find solutions for the delay in the settlement of the amounts owed to the hospitals,” Haroun added.
 
Arab Hospitals Federation

Jabak then met with a delegation from the Arab Hospitals Federation that invited him to attend the “Arab Hospitals Federation Forum in Cairo” that will be held in conjunction with the Council of Arab Ministers of Health on 27 and 28 February. The delegation also invited him to attend the Arab Hospitals Federation Conference” that will be held next 10 and 11 April in Kuwait.
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
L04AB06 SIMPONI BioTech Golimumab - 100mg/1ml 100mg/1ml Injectable solution 72,719,241 L.L
L04AC05 STELARA BioTech Ustekinumab - 45mg 45mg Injectable solution 151,777,679 L.L
L04AC05 STELARA BioTech Ustekinumab - 90mg 90mg Injectable solution 151,777,679 L.L
M03AC11 SISACURE G Cisatracurium (besylate) - 20mg/10ml 20mg/10ml Injectable solution 1,408,347 L.L
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 4.2g/100ml 4.2g/100ml Injectable solution 742,370 L.L
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 8.4g/100ml 8.4% Injectable solution 959,565 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 75mg 75mg Injectable solution 194,911,251 L.L
B05XA02 SODIUM BICARBONATE G Sodium bicarbonate - 1.4g/100ml 1.4g/100ml Injectable solution 258,887 L.L
L04AC18 SKYRIZI BioTech Risankizumab - 150mg 150mg Injectable solution 194,911,251 L.L
H01CB02 SANDOSTATIN B Octreotide - 0.1mg/ml 0.1mg/ml Injectable solution 1,038,790 L.L
J02AC01 STABILANOL G Fluconazole - 2mg/ml 2mg/ml Injectable solution 1,242,583 L.L
H01CB03 SOMATULINE AUTOGEL B Lanreotide (acetate) - 90mg 90mg Injectable solution 48,383,450 L.L
H01CB03 SOMATULINE AUTOGEL B Lanreotide (acetate) - 120mg 120mg Injectable solution 57,492,826 L.L
H01CB05 SIGNIFOR B Pasireotide (diaspartate) - 0.3mg/ml 0.3mg/ml Injectable solution 168,719,438 L.L
H01CB05 SIGNIFOR B Pasireotide (diaspartate) - 0.6mg/ml 0.6mg/ml Injectable solution 180,355,261 L.L
H01CB05 SIGNIFOR B Pasireotide (diaspartate) - 0.9mg/ml 0.9mg/ml Injectable solution 183,846,008 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION USP G Sodium chloride - 0.9% 0.9% Injectable solution 165,482 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 176,974 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 163,184 L.L
B05XA03 SERUFLEX SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9% 0.9% Injectable solution 156,288 L.L
A10AE54 SULIQUA BioTech Insulin glargine - 100IU/ml, Lixisenatide - 50mcg/ml Injectable solution 11,286,573 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 4,143,943 L.L
A10AE54 SULIQUA BioTech Insulin glargine - 100IU/ml, Lixisenatide - 33mcg/ml Injectable solution 7,975,793 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 3,985,356 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 5,566,628 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 519,736 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 167,780 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 167,780 L.L
B05XA03 SODIUM CHLORIDE G Sodium chloride - 0.9% 0.9% Injectable solution 166,708 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025